Market closed
Cue Biopharma/$CUE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cue Biopharma
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Ticker
$CUE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
41
Website
Cue Biopharma Metrics
BasicAdvanced
$57M
-
-$0.72
2.03
-
Price and volume
Market cap
$57M
Beta
2.03
52-week high
$2.26
52-week low
$0.45
Average daily volume
180K
Financial strength
Current ratio
1.836
Quick ratio
1.778
Long term debt to equity
5.732
Total debt to equity
50.723
Interest coverage (TTM)
-52.25%
Management effectiveness
Return on assets (TTM)
-55.47%
Return on equity (TTM)
-149.03%
Valuation
Price to revenue (TTM)
4.56
Price to book
2.66
Price to tangible book (TTM)
2.66
Price to free cash flow (TTM)
-1.164
Growth
Revenue change (TTM)
69.16%
Earnings per share change (TTM)
-34.88%
3-year revenue growth (CAGR)
-14.66%
3-year earnings per share growth (CAGR)
-20.02%
What the Analysts think about Cue Biopharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cue Biopharma stock.
Cue Biopharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Cue Biopharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Cue Biopharma News
AllArticlesVideos
Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)
Seeking Alpha·2 weeks ago
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
GlobeNewsWire·3 weeks ago
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cue Biopharma stock?
Cue Biopharma (CUE) has a market cap of $57M as of May 03, 2025.
What is the P/E ratio for Cue Biopharma stock?
The price to earnings (P/E) ratio for Cue Biopharma (CUE) stock is 0 as of May 03, 2025.
Does Cue Biopharma stock pay dividends?
No, Cue Biopharma (CUE) stock does not pay dividends to its shareholders as of May 03, 2025.
When is the next Cue Biopharma dividend payment date?
Cue Biopharma (CUE) stock does not pay dividends to its shareholders.
What is the beta indicator for Cue Biopharma?
Cue Biopharma (CUE) has a beta rating of 2.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.